Cargando…
Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors
BACKGROUND: Clinical trials report systemic hypertension is an adverse effect of vascular signalling pathway inhibitor (VSPi) use. There are limited data from routine clinical practice. We aimed to estimate the real-world incidence and risk factors of new-onset and aggravated hypertension for cancer...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777550/ https://www.ncbi.nlm.nih.gov/pubmed/35201530 http://dx.doi.org/10.1007/s12672-022-00468-3 |